Health Care·Pharmaceuticals·$277.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.53 | N/A | -6.54% |
management commentary, guidance changes, and full analysis available with Pro.
| -6.54% |
Tone: Defensive
Management expressed concerns about ongoing market challenges impacting performance. They remain focused on long-term strategies.
Management acknowledged challenges in the current market environment.
They emphasized a focus on long-term growth despite short-term pressures.
The earnings report indicates that Novartis faced challenges in the fourth quarter, leading to an EPS miss. The stock reacted negatively, dropping nearly 4%. Investors may be cautious as management highlighted ongoing market pressures without providing guidance for the future.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
KONINKLIJKE PHILIPS ADR
Jan 29, 2024